208 related articles for article (PubMed ID: 34944600)
21. Selection and characterization of human PCSK9 antibody from phage displayed antibody library.
Cao Y; Yang H; Zhou X; Mao H; Gao T; Hu Z; He L; Pan F; Guo Z
Biochem Biophys Res Commun; 2015 Aug; 463(4):712-8. PubMed ID: 26056005
[TBL] [Abstract][Full Text] [Related]
22. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
23. Molecular basis for LDL receptor recognition by PCSK9.
Kwon HJ; Lagace TA; McNutt MC; Horton JD; Deisenhofer J
Proc Natl Acad Sci U S A; 2008 Feb; 105(6):1820-5. PubMed ID: 18250299
[TBL] [Abstract][Full Text] [Related]
24. Single-Strand DNA-Like Oligonucleotide Aptamer Against Proprotein Convertase Subtilisin/Kexin 9 Using CE-SELEX: PCSK9 Targeting Selection.
Sattari R; Palizban A; Khanahmad H
Cardiovasc Drugs Ther; 2020 Aug; 34(4):475-485. PubMed ID: 32415571
[TBL] [Abstract][Full Text] [Related]
25. Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.
Geschwindner S; Andersson GM; Beisel HG; Breuer S; Hallberg C; Kihlberg BM; Lindqvist AM; O'Mahony G; Plowright AT; Raubacher F; Knecht W
Protein Eng Des Sel; 2015 May; 28(5):117-25. PubMed ID: 25744035
[TBL] [Abstract][Full Text] [Related]
26. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D
J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270
[TBL] [Abstract][Full Text] [Related]
27. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
Shen L; Peng H; Xu D; Zhao S
Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
[TBL] [Abstract][Full Text] [Related]
28. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
29. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.
Carreras A; Pane LS; Nitsch R; Madeyski-Bengtson K; Porritt M; Akcakaya P; Taheri-Ghahfarokhi A; Ericson E; Bjursell M; Perez-Alcazar M; Seeliger F; Althage M; Knöll R; Hicks R; Mayr LM; Perkins R; Lindén D; Borén J; Bohlooly-Y M; Maresca M
BMC Biol; 2019 Jan; 17(1):4. PubMed ID: 30646909
[TBL] [Abstract][Full Text] [Related]
30. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
31. Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome.
Wang M; Zhao D; Xu L; Guo W; Nie L; Lei Y; Long Y; Liu M; Wang Y; Zhang X; Zhang L; Li H; Zhang J; Yuan D; Yue L
Metabolism; 2019 May; 94():47-58. PubMed ID: 30768966
[TBL] [Abstract][Full Text] [Related]
32. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.
Hopkins PN; Krempf M; Bruckert E; Donahue S; Yang F; Zhang Y; DiCioccio AT
J Clin Lipidol; 2019; 13(6):970-978. PubMed ID: 31767518
[TBL] [Abstract][Full Text] [Related]
34. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.
Graham MJ; Lemonidis KM; Whipple CP; Subramaniam A; Monia BP; Crooke ST; Crooke RM
J Lipid Res; 2007 Apr; 48(4):763-7. PubMed ID: 17242417
[TBL] [Abstract][Full Text] [Related]
35. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
Lu X
Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
[TBL] [Abstract][Full Text] [Related]
36. Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering.
Kirchhofer D; Burdick DJ; Skelton NJ; Zhang Y; Ultsch M
Biochem Soc Trans; 2020 Aug; 48(4):1323-1336. PubMed ID: 32794575
[TBL] [Abstract][Full Text] [Related]
37. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
[TBL] [Abstract][Full Text] [Related]
38. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement.
Henne KR; Ason B; Howard M; Wang W; Sun J; Higbee J; Tang J; Matsuda KC; Xu R; Zhou L; Chan JC; King C; Piper DE; Ketchem RR; Michaels ML; Jackson SM; Retter MW
J Pharmacol Exp Ther; 2015 Apr; 353(1):119-31. PubMed ID: 25653417
[TBL] [Abstract][Full Text] [Related]
39. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
Tavori H; Melone M; Rashid S
Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
[TBL] [Abstract][Full Text] [Related]
40. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
Liang H; Chaparro-Riggers J; Strop P; Geng T; Sutton JE; Tsai D; Bai L; Abdiche Y; Dilley J; Yu J; Wu S; Chin SM; Lee NA; Rossi A; Lin JC; Rajpal A; Pons J; Shelton DL
J Pharmacol Exp Ther; 2012 Feb; 340(2):228-36. PubMed ID: 22019884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]